Defibrillators, replacement joints, pacemakers, insulin and lidocaine: All are made in China, and all are among the items targeted by the Trump administration’s tariffs.
Pacemakers and artificial joints. Defibrillators. Dental fillings. Birth-control pills and vaccines. All are made in China, and all could be subject to new tariffs.
Dozens of drugs and medical devices are among the Chinese products and ingredients that the Trump administration targeted for a potential 25 percent tariff in a proposal this week. The list includes some products that are in dangerously short supply, like epinephrine, used to treat allergic reactions, and others, like insulin, whose rising prices have driven public outrage in the United States.
The proposed tariffs have unsettled the medical device and supply industries, given that a growing number of products, as well as their components, are now manufactured in China. In recent years, as trade groups have noted, Chinese manufacturing of medical equipment has undergone a major shift from throwaway items like surgical gloves to more complicated products like magnetic resonance imaging scanners.
China’s medical device industry has been expanding rapidly. An International Trade Commission report in January said the fastest growth was in sales of implantable orthopedic devices, plates and screws, mostly made of titanium and used for surgery and sports medicine. One analyst estimates that about 12 percent of medical devices imported into the United States come from China, amounting to $3 billion a year.
Several companies, including Medtronic and Zimmer Biomet, have orthopedic device factories in China that export goods to the United States.
In 2012, Medtronic, considered the world’s leading medical-device maker, bought China Kanghui Holdings, a major provider of orthopedic devices in China. Any products shipped from those operations to the United States would be subject to the tariffs. Medtronic declined to comment, saying it was still reviewing the proposal.
And a report this week by RBC Capital Markets estimated that if the proposed 25 percent tariffs took effect, the move could cost the medical device industry up to $1.5 billion each year. Some of the higher costs would undoubtedly result in increased prices for those devices, affecting baby boomers, who are now among the biggest recipients of hip and knee replacements.
Brandon Henry, a medical device analyst for RBC Capital Markets, said some of the bigger medical technology companies were surprised to find their products on the list.
Greg Crist, a spokesman for AdvaMed, the trade group for device members, said its members were “disappointed because this action threatens to affect the health and well-being of American patients and those around the world.”
How much would be passed on to consumers remains unknown.
“The impact of this orthopedic device tariff isn’t a straight line,” said David A. Halsey, president of the American Academy of Orthopaedic Surgeons, in an email, adding that the group was working to assess the possible effects.
It is still unclear whether the tariffs will be enacted: Companies have until May to lobby the administration for changes. But on Friday, President Trump ratcheted up the pressure by threatening to levy tariffs on an additional $100 billion in imports, provoking China to respond that it would strike back yet again.
Indeed, stocks of drug manufacturers remained largely unruffled after the unveiling of the list on Tuesday, but by Friday, the major medical device company stocks had dipped along with the overall market. Medtronic shares were 2.7 percent lower for the week, and Zimmer Biomet was down 2.4 percent.
It was unclear whether the tariffs would have a substantial effect on the drug industry, analysts said, even though China is a leading exporter of raw pharmaceutical ingredients. “We don’t see much impact,” Umer Raffat, a pharmaceutical industry analyst for Evercore ISI, said in a note to investors on Tuesday.
That is because many generic drugs that contain Chinese ingredients are manufactured in countries like India, meaning they would not be subject to the tariffs. And brand-name drugs made in the United States are frequently so expensive that the list price often has little connection to the product’s manufacturing cost.
Nevertheless, at least one trade group sounded the alarm on the tariffs, warning that they could exacerbate the already contentious issue of health care costs, just when the Trump administration has pledged to take action to lower drug prices.
“We are concerned that the proposed tariffs may lead to increased costs of manufacturing for generics and biosimilars and thus higher prescription drug prices for patients in the U.S.,” said Jeffrey K. Francer, senior vice president and general counsel at the Association for Accessible Medicines, which represents generic-drug companies. The generic business has been struggling with falling prices even as brand-name drug prices have risen.
Several major manufacturers, including Pfizer, Merck and the generic-drug makers Mylan and Teva Pharmaceutical declined to comment.
“The cynic in me thinks this is another way for companies to say they need to raise their prices,” said Erin R. Fox, a drug-shortage expert at the University of Utah.
Ms. Fox said she suspected that the tariffs could exacerbate shortfalls of generic injectable drugs — decades-old products that are mainstays in hospitals and have been in short supply for years because of manufacturing problems and supply disruptions.
While many pill forms of generic drugs are manufactured overseas, most generic injectable drugs are made in the United States, using raw ingredients acquired from overseas. But because many companies do not disclose where those raw ingredients come from — saying the information is proprietary — it is hard to know the impact of the proposed tariffs, Ms. Fox said.
Two drugs on the list of 1,300 Chinese exports are epinephrine and lidocaine, which are both in short supply in their sterile injectable form.
“Things are so bad right now with the injectables, we don’t need anything else to pile on, to possibly make things worse,” Ms. Fox said.
Heather Zoumas Lubeski, a spokeswoman for Par Pharmaceutical, a major manufacturer of injectable epinephrine, said the company’s raw ingredients were imported from Europe and that the proposed tariffs would not have an impact on Par or its parent company, Endo International.
Even for some widely used products, it is unclear how American consumers would be affected. While insulin is on the list, all three major companies that sell insulin in the United States — Eli Lilly, Sanofi and Novo Nordisk — said they did not import insulin from China. (Novo Nordisk said that one rarely used insulin product, the NovoPen Echo, does come from China, but that the company was committed to keeping it accessible to consumers.)
Some analysts and trade lawyers pointed out that the list was an early draft and that many different industries and groups would be lobbying the government in the coming months so that their products would not be punished.